schizophrenia

Photo
09.01.2025 • News

Newron Licenses Evenamide to Myung In Pharm

Newron Pharmaceuticals, a central nervous system (CNS) focused biopharmaceutical company, and Myung In Pharm, South Korea’s leading CNS pharmaceutical company, today announced that they have entered into a license agreement to develop, manufacture, and commercialize Newron’s schizophrenia treatment evenamide. 

Photo
13.12.2024 • News

Newron Licenses Schizophrenia Treatment to EA Pharma

Italian drugmaker Newron Pharmaceuticals and EA Pharma, a subsidiary of Japan’s Eisai, today have entered into a license agreement to develop, manufacture and commercialize Newron’s evenamide in Japan and other designated Asian territories.

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.